接受所有 Cookie 可以确保在我们网站上获得良好的用户体验,包括个性化的内容和社交媒体功能。仅接受必要的 Cookie 将在您浏览时使用最少的 Cookie,但是网站上的部分内容可能无法正确显示。如需了解更多信息,请查看我们的 隐私政策。
Amplexor in European Biopharmaceutical Review
by Romuald Braun, VP of Strategy at Amplexor
With regulatory compliance growing, we should expect to see data management transformation rising. However, this is not the case. Instead, we see companies throwing good money after bad money as they opt to invest in digitizing a process or updating an existing IT system. While, encouragingly, in 2019 organisations now appear to recognize the need for a more holistic approach, Life Sciences companies will need to focus attention on developing a vision for delivering this and mapping it to a hard strategy. Read the full article and learn more about why it's important for Life Sciences companies to move from approaching each project in isolation, to viewing them as part of a bigger vision.
This article is taken from European Biopharmaceutical Review January 2019, pages 86-87. © Samedan Ltd.